{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:10:41Z","timestamp":1770703841636,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T00:00:00Z","timestamp":1134345600000},"content-version":"vor","delay-in-days":3116,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[1997,6]]},"abstract":"Abstract<\/jats:title>Objective.<\/jats:italic> To assess levels of soluble Fas (sFas) and soluble Fas ligand (sFas\u2010L) in sera from patients with various rheumatic diseases: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis\/dermatomyositis (PM\/DM), mixed connective tissue disease (MCTD), and Sj\u00f6gren's syndrome (SS).<\/jats:p>Methods.<\/jats:italic> Levels of sFas and sFas\u2010L were determined by a sandwich enzyme\u2010linked immunosorbent assay.<\/jats:p>Results.<\/jats:italic> In SLE, PM\/DM, MCTD, and SS, sFas levels were significantly higher compared with normal controls. Levels of sFas in the SLE patients were significantly higher than in patients with other rheumatic diseases. Levels of sFas\u2010L were significantly increased in SS patients. SLE and RA patients with high levels sFas\u2010L tended to have high levels of sFas, while sFas and sFasL levels did not correlate in patients with other diseases. In some of the SLE patients, sFas and sFas\u2010L levels decreased following steroid therapy.<\/jats:p>Conclusion.<\/jats:italic> Serum sFas and sFas\u2010L levels were significantly higher in some rheumatic disease patients. Since these changes are complex in these rheumatic diseases, it may be difficult to directly relate sFas and sFasL to their pathogenesis.<\/jats:p>","DOI":"10.1002\/art.1780400617","type":"journal-article","created":{"date-parts":[[2007,2,14]],"date-time":"2007-02-14T12:42:54Z","timestamp":1171456974000},"page":"1126-1129","source":"Crossref","is-referenced-by-count":102,"title":["Soluble Fas (APO\u20101, CD95) and soluble Fas ligand in rheumatic diseases"],"prefix":"10.1002","volume":"40","author":[{"given":"Kazuhisa","family":"Nozawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kayagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Tokano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yagita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hasimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,12,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/373444a0"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/356314a0"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","unstructured":"EmlenW NieburJ KaderaR: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus.J Immunol3685\u20133692 1994","DOI":"10.4049\/jimmunol.152.7.3685"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7510905"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90326-L"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.8.3806"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07096.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0396-317"},{"key":"e_1_2_1_10_2","volume-title":"Mixed Connective Tissue Disese and Antinuclear Antibodies","author":"Alarc\u00f3n\u2010Segovia D","year":"1987"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380105"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.4.1547"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.6.1777"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381205"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780381206"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.1780400617","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.1780400617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T21:13:14Z","timestamp":1700773994000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.1780400617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1002\/art.1780400617"],"URL":"https:\/\/doi.org\/10.1002\/art.1780400617","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}